Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332761 · ClinicalTrials.gov registry record · Phase 4
Caduet in an Untreated Subject Population
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 220
- Enrollment target
NCT00332761 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 220 participants.
The verdict
NCT00332761, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Caduet will lower blood pressure to \<140/90 mmHg and lower LDL Cholesterol to \<100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.
Interventions
- DRUG Caduet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00332761
The ClinicalTrials.gov registry entry for NCT00332761 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Caduet is the first listed.
NCT00332761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00332761 about?
NCT00332761 is a clinical study titled "Caduet in an Untreated Subject Population". The purpose of this study is to determine if Caduet will lower blood pressure to \<140/90 mmHg and lower LDL Cholesterol to \<100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.
What is the current status of trial NCT00332761?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2006-06. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00332761?
The interventions under investigation include: Caduet (DRUG).
Who is sponsoring clinical trial NCT00332761?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.